{"id":"sa4ag-vaccine","_chembl":null,"modality":"Biologic","_dailymed":null,"mechanism":{"explanation":"As a vaccine, SA4Ag likely works by presenting antigens to the immune system to generate protective antibodies and/or cellular immunity. The specific antigens, adjuvants, and immune pathways involved have not been publicly characterized.","oneSentence":"SA4Ag is a vaccine designed to elicit an immune response against specific antigens, though the exact mechanism has not been publicly disclosed."},"_scrapedAt":"2026-03-28T06:48:31.575Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122953,"model":"claude-sonnet-4-5-20250929"},"description":"SA4Ag is an investigational vaccine developed by Pfizer currently in Phase 1 clinical trials. As a vaccine candidate, it is designed to stimulate an immune response, though its specific molecular target, therapeutic indication, and mechanism of action have not been publicly disclosed.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT02388165","phase":"PHASE2","title":"Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation","status":"TERMINATED","sponsor":"Pfizer","startDate":"2015-07-02","conditions":"Staphylococcal Vaccine","enrollment":3450},{"nctId":"NCT01364571","phase":"PHASE1","title":"Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-08","conditions":"Staphylococcal Infections","enrollment":456},{"nctId":"NCT01643941","phase":"PHASE1","title":"Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-08","conditions":"Staphylococcal Infections","enrollment":284},{"nctId":"NCT02492958","phase":"PHASE2","title":"SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-06","conditions":"Staphylococcal Infections","enrollment":136},{"nctId":"NCT02364596","phase":"PHASE1","title":"Evaluation of a Single Vaccination With a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-01","conditions":"Staphylococcal Infections","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"SA4Ag vaccine","genericName":"SA4Ag vaccine","companyName":"Pfizer","companyId":"pfizer","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":3,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}